- •Primary aldosteronism (PA) is relatively common cause of difficult-to-control hypertension.
- •Unrecognized and untreated PA increases risk of cardiac and renal complications.
- •Initial workup of high-risk patients should include plasma aldosterone and renin levels.
- •Patients with elevated aldosterone and suppressed renin should be referred to specialty care.
- •Spironolactone is a drug of choice in treatment of bilateral adrenal hyperplasia.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association.Hypertension. 2018; 72: e53-e90https://doi.org/10.1161/HYP.0000000000000084
- Endocrine hypertension: a primer for primary care nurse practitioners.J Nurse Pract. 2019; 15: 782-786
- Diagnosis and treatment of primary aldosteronism: practical clinical perspectives.J Intern Med. 2019; 285: 126-148https://doi.org/10.1111/joim.12831
- Diagnosis and treatment of primary aldosteronism.Lancet Diabetes Endocrinol. 2021; 9: 876-892https://doi.org/10.1016/S2213-8587(21)00210-2
- A young man with severe hypertension.BMJ. 2018; 362: k2935https://doi.org/10.1136/bmj.k2935
- Primary aldosteronism: a common cause of resistant hypertension.CMAJ. 2017; 189: 773-778https://doi.org/10.1503/cmaj.161486
Publication stageIn Press Corrected Proof
In compliance with standard ethical guidelines, the authors report no relationships with business or industry that would pose a conflict of interest.